Kiniksa Pharmaceuticals International, plc Increase (Decrease) in Accounts Receivable
Kiniksa Pharmaceuticals International, plc (KNSA) reported Increase (Decrease) in Accounts Receivable of $7.63 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-28.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-04-28
- Kiniksa Pharmaceuticals International, plc increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $7.63M.
- Kiniksa Pharmaceuticals International, plc increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$36.15M, a 314.71% decline year-over-year.
- Kiniksa Pharmaceuticals International, plc increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $19.83M, a 346.97% increase year-over-year.
- Kiniksa Pharmaceuticals International, plc increase (decrease) in accounts receivable for the quarter ending 2025-06-30 was -$8.15M, a 283.01% decline year-over-year.
- Kiniksa Pharmaceuticals International, plc increase (decrease) in accounts receivable for fiscal 2025 was -$26.13M, a 227.73% decline from fiscal 2024.
- Kiniksa Pharmaceuticals International, plc increase (decrease) in accounts receivable for fiscal 2024 was $20.46M, a 137.72% increase from fiscal 2023.
- Kiniksa Pharmaceuticals International, plc increase (decrease) in accounts receivable for fiscal 2023 was $8.61M, a 0.80% decline from fiscal 2022.
- Kiniksa Pharmaceuticals International, plc increase (decrease) in accounts receivable for fiscal 2022 was $8.68M, a 121.87% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-03-31 | $7.63M 10-Q · filed 2026-04-28 | -$28.52M derived: sum of 2 quarters · filed 2026-04-28 | -$8.69M derived: sum of 3 quarters · filed 2026-04-28 | -$16.84M derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-12-31 | -$36.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$16.32M derived: sum of 2 quarters · filed 2026-02-24 | -$24.47M derived: sum of 3 quarters · filed 2026-02-24 | -$26.13M 10-K · filed 2026-02-24 |
| 2025-09-30 | $19.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $11.68M derived: sum of 2 quarters · filed 2025-10-28 | $10.02M 10-Q · filed 2025-10-28 | $26.85M derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-06-30 | -$8.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | -$9.81M 10-Q · filed 2025-07-29 | $7.02M derived: sum of 3 quarters · filed 2026-04-28 | $11.46M derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-03-31 | -$1.66M 10-Q · filed 2026-04-28 | $15.18M derived: sum of 2 quarters · filed 2026-04-28 | $19.61M derived: sum of 3 quarters · filed 2026-04-28 | $24.07M derived: sum of 4 quarters · filed 2026-04-28 |
| 2024-12-31 | $16.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $21.27M derived: sum of 2 quarters · filed 2026-02-24 | $25.73M derived: sum of 3 quarters · filed 2026-02-24 | $20.46M 10-K · filed 2026-02-24 |
| 2024-09-30 | $4.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $8.89M derived: sum of 2 quarters · filed 2025-10-28 | $3.62M 10-Q · filed 2025-10-28 | $21.85M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $4.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | -$815.00K 10-Q · filed 2025-07-29 | $17.41M derived: sum of 3 quarters · filed 2026-02-24 | -$4.20M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | -$5.27M 10-Q · filed 2025-04-29 | $12.95M derived: sum of 2 quarters · filed 2026-02-24 | -$8.65M derived: sum of 3 quarters · filed 2026-02-24 | $8.57M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $18.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$3.38M derived: sum of 2 quarters · filed 2026-02-24 | $13.84M derived: sum of 3 quarters · filed 2026-02-24 | $8.61M 10-K · filed 2026-02-24 |
| 2023-09-30 | -$21.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-29 | -$4.38M derived: sum of 2 quarters · filed 2024-10-29 | -$9.62M 10-Q · filed 2024-10-29 | -$8.12M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $17.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-25 | $11.99M 10-Q · filed 2024-07-25 | $13.49M derived: sum of 3 quarters · filed 2025-02-25 | $16.84M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | -$5.24M 10-Q · filed 2024-04-25 | -$3.73M derived: sum of 2 quarters · filed 2025-02-25 | -$384.00K derived: sum of 3 quarters · filed 2025-02-25 | -$22.02M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $4.85M derived: sum of 2 quarters · filed 2025-02-25 | -$16.78M derived: sum of 3 quarters · filed 2025-02-25 | $8.68M 10-K · filed 2025-02-25 |
| 2022-09-30 | $3.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$18.28M derived: sum of 2 quarters · filed 2023-11-02 | $7.17M 10-Q · filed 2023-11-02 | $7.86M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | -$21.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | $3.82M 10-Q · filed 2023-08-01 | $4.51M derived: sum of 3 quarters · filed 2024-02-28 | $5.18M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $25.45M 10-Q · filed 2023-05-04 | $26.14M derived: sum of 2 quarters · filed 2024-02-28 | $26.81M derived: sum of 3 quarters · filed 2024-02-28 | |
| 2021-12-31 | $686.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $1.36M derived: sum of 2 quarters · filed 2024-02-28 | $3.91M 10-K · filed 2024-02-28 | |
| 2021-09-30 | $673.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $3.22M 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | $2.55M 10-Q · filed 2022-08-04 |